NVP-BEZ235 Inhibits Renal Cell Carcinoma by Targeting TAK1 and PI3K/Akt/mTOR Pathways
In spite of the promising in vitro and preclinical results, dual PI3K/Akt/mTOR inhibitor NVP-BEZ235, and ATP-competitive mTOR inhibitor PP242 both failed to confirm their inhibitory efficacy against renal cell carcinoma (RCC) in clinical settings. Therefore, a better understanding of the molecular m...
Na minha lista:
| Principais autores: | , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Frontiers Media S.A.
2022-01-01
|
| coleção: | Frontiers in Pharmacology |
| Assuntos: | |
| Acesso em linha: | https://www.frontiersin.org/articles/10.3389/fphar.2021.781623/full |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|